Cardiovascular Peptides: A Guide to Antithrombotics, Natriuretic Peptides, and RAAS Peptides

Cardiovascular pharmacology uses peptides in narrowly defined, high-leverage situations. The first is anticoagulation during percutaneous coronary intervention (PCI), where bivalirudin — a 20-amino-acid synthetic direct thrombin inhibitor derived from leech hirudin — is administered intravenously in the catheterization laboratory. Its value is not that it is a peptide per se, but that its reversible dual-site binding to thrombin and ~25-minute half-life give interventional cardiologists predictable anticoagulation with rapid offset once the infusion stops. That pharmacokinetic profile is difficult to achieve with small molecules.

The second is platelet-aggregation inhibition during acute coronary syndromes, where eptifibatide, a cyclic heptapeptide derived from pygmy rattlesnake venom, occupies the fibrinogen-binding pocket of the platelet GPIIb/IIIa receptor. Again, the peptide origin matters because the natural disintegrin template provided a high-affinity, integrin-selective scaffold that would be hard to find in a small-molecule library.

The third is acute decompensated heart failure, where nesiritide (recombinant human B-type natriuretic peptide) briefly became a first-line option for patients with dyspnea at rest. The ASCEND-HF trial subsequently narrowed its role — more on this below — but the natriuretic peptide family remains central to how cardiologists think about volume status and neurohormonal regulation.

Beyond these FDA-approved cases, the cardiovascular research literature is dense with peptide work: endothelin-1 as a target, angiotensin-II as a reference ligand, angiotensin-(1-7) as a candidate counter-regulator, RGDS as a foundational integrin-binding motif. None of those are therapeutics, but all of them shape how new drugs are designed and studied.

Bivalirudin (brand name Angiomax) is a 20-amino-acid synthetic analog of hirudin, the anticoagulant secreted by the medicinal leech Hirudo medicinalis. It is an FDA-approved direct thrombin inhibitor used during PCI and in patients with heparin-induced thrombocytopenia (HIT). Mechanistically, it binds two distinct sites on the thrombin molecule simultaneously — the catalytic active site and the anion-binding exosite 1, which is the site thrombin uses to recognize fibrinogen. This bivalent engagement distinguishes bivalirudin from univalent thrombin inhibitors and provides very specific thrombin blockade, including inhibition of clot-bound thrombin that heparin cannot reach.

The clinical evidence base is extensive. The REPLACE-2 trial (n=6,010) established non-inferiority to heparin plus a GPIIb/IIIa inhibitor for ischemic endpoints during PCI, with significantly lower bleeding rates. HORIZONS-AMI, a large STEMI trial, showed a 40% reduction in 30-day major bleeding versus heparin-plus-GPI and a 3-year cardiac mortality benefit. Later trials including EUROMAX and HEAT-PPCI produced more mixed results on net clinical benefit, leading to some decline in routine use as heparin monotherapy with selective GPIIb/IIIa rescue became the preferred alternative in many centers.

A critical feature is thrombin's ability to slowly cleave bivalirudin at the Arg3-Pro4 bond, which means inhibition is gradually reversible as drug concentration falls. Combined with a half-life of approximately 25 minutes in normal renal function (extending to ~57 minutes in severe renal impairment), this gives bivalirudin the controllability that catheterization labs value. Direct oral anticoagulants (DOACs) have eroded its outpatient role, but the periprocedural indication remains.

Eptifibatide (Integrilin) is an FDA-approved cyclic heptapeptide derived from barbourin, a disintegrin isolated from the venom of the southeastern pygmy rattlesnake. It reversibly occupies the fibrinogen-binding pocket of the platelet glycoprotein IIb/IIIa receptor — the final common pathway of platelet aggregation — through a KGD (Lys-Gly-Asp) sequence that mimics the classic RGD recognition motif. By preventing fibrinogen cross-linking between activated platelets, eptifibatide blocks aggregation regardless of the upstream activation signal. Platelet function recovers within 4–8 hours of discontinuation, a deliberately short offset that distinguishes it from the irreversible monoclonal abciximab.

The PURSUIT trial (n=10,948) demonstrated reduction in the composite of death or myocardial infarction at 30 days in non-ST-elevation ACS, and ESPRIT confirmed benefit when eptifibatide is given as a PCI adjunct. Together these trials underwrote FDA approval in 1998. Eptifibatide remains a standard component of high-risk ACS and PCI management in hospitals worldwide, alongside its class peers abciximab and tirofiban.

RGDS — the four-amino-acid Arg-Gly-Asp-Ser peptide — is not a therapeutic. It is the prototypical recognition motif through which integrins bind fibrinogen, fibronectin, vitronectin, and many other extracellular-matrix ligands. RGDS is used extensively in cardiovascular and oncology research as a receptor probe: to block integrin-mediated platelet aggregation in vitro, to disrupt tumor-cell adhesion, and to serve as a design template for therapeutics like eptifibatide and tirofiban. The peptide is research-grade only; it has no clinical use.

The natriuretic peptide family — atrial natriuretic peptide (ANP), B-type (or brain) natriuretic peptide (BNP), and C-type natriuretic peptide (CNP) — regulates intravascular volume, vascular tone, and sodium excretion. ANP and BNP share the same transmembrane receptor, natriuretic peptide receptor A (NPR-A), a guanylyl cyclase whose activation generates the intracellular second messenger cyclic GMP (cGMP). Elevated cGMP drives balanced arterial and venous vasodilation, promotes renal sodium excretion, and suppresses the renin-angiotensin-aldosterone system and sympathetic drive — all effects that oppose the pathophysiology of heart failure.

Nesiritide (Natrecor) is an FDA-approved recombinant human B-type natriuretic peptide structurally identical to endogenous BNP-32. It was approved in 2001 for acutely decompensated heart failure based on the VMAC trial, which showed significant reductions in pulmonary capillary wedge pressure. The drug was adopted widely in the mid-2000s. A 2005 meta-analysis subsequently raised concerns about increased 30-day mortality and worsening renal function, prompting a boxed warning and the definitive ASCEND-HF trial (n=7,141). ASCEND-HF showed nesiritide produced only modest dyspnea relief and did not reduce mortality or rehospitalization, sharply narrowing its clinical role.

Recombinant ANP — carperitide (Hanp) — is used in Japan for acute decompensated heart failure but was not adopted in the United States, largely because approval pre-dated modern outcomes-trial expectations and because nesiritide's trajectory discouraged parallel US development. The natriuretic peptide system nonetheless remains diagnostically central: BNP and NT-proBNP are standard biomarkers for heart failure severity and prognosis, and the endogenous pathway is now pharmacologically exploited by the combination neprilysin-inhibitor sacubitril-valsartan, which augments endogenous BNP signaling by blocking its degradation.

Endothelin-1 (ET-1) is a 21-amino-acid peptide produced primarily by vascular endothelial cells. It is the most potent endogenous vasoconstrictor identified to date, roughly ten times more potent than angiotensin-II on a molar basis. ET-1 signals through two G-protein-coupled receptor subtypes: ETA, expressed predominantly on vascular smooth muscle, where it drives vasoconstriction and smooth-muscle proliferation; and ETB, expressed on endothelial cells (where it promotes nitric oxide release and ET-1 clearance) and on smooth muscle (where it also drives vasoconstriction). The balance between these actions shapes vascular tone and pulmonary vascular remodeling.

As a peptide, ET-1 itself is a research reagent, not a drug. Its pharmacologic relevance is the reverse: ET-1 is the target that underlies an entire class of FDA-approved oral endothelin receptor antagonists (ERAs) — bosentan, ambrisentan, and macitentan — used in pulmonary arterial hypertension (PAH). These drugs do not administer ET-1; they block its receptors. The fact that such a focused class exists reflects how cleanly the ET-1/ETA axis connects to PAH pathophysiology.

Research use of synthetic ET-1 peptide spans receptor-pharmacology experiments, vasoreactivity studies in isolated vessels, models of acute kidney injury and pulmonary vascular remodeling, and as a positive control in screening assays. Small clinical studies have also used intra-arterial ET-1 to probe endothelial function in humans. None of this is therapeutic. The therapeutic angle lives on the antagonist side of the pathway.

The renin-angiotensin-aldosterone system (RAAS) is the best-characterized peptidergic axis in cardiovascular medicine. Renin cleaves angiotensinogen to produce angiotensin-I; ACE cleaves angiotensin-I to produce angiotensin-II (Ang II), the classical effector peptide. Ang II binds AT1 receptors to drive vasoconstriction, aldosterone secretion, sympathetic activation, and, over time, vascular and cardiac remodeling. Outpatient cardiovascular practice largely consists of inhibiting this axis — ACE inhibitors, angiotensin-receptor blockers, mineralocorticoid antagonists, and now sacubitril-valsartan.

Ang II also has a therapeutic identity of its own. Synthetic angiotensin-II (brand name Giapreza) was FDA-approved in 2017 for catecholamine-resistant vasodilatory shock in critically ill adults. The ATHOS-3 trial demonstrated it raised mean arterial pressure in distributive shock patients who had failed norepinephrine and vasopressin, though its role is still debated and use remains limited to specialist ICU settings.

Angiotensin-(1-7) is a seven-amino-acid peptide generated primarily by ACE2 cleaving Ang II. It signals through the Mas receptor and is increasingly framed as the counter-regulatory arm of the RAAS — broadly vasodilatory, anti-proliferative, anti-fibrotic, and anti-inflammatory. Preclinical and early human work suggests potential in hypertension, heart failure, diabetic complications, and pulmonary disease. None of this has produced an FDA-approved angiotensin-(1-7)-based drug as of 2026, and short plasma half-life remains a development hurdle. The axis is under active investigation, and modified analogs with improved pharmacokinetics are being pursued.

It is worth being explicit about where each peptide in this guide sits in 2026. Bivalirudin, eptifibatide, and nesiritide are FDA-approved, in clinical use, and stocked in hospital pharmacies — though nesiritide's use is much diminished post-ASCEND-HF. Synthetic angiotensin-II (Giapreza) is FDA-approved but niche, reserved for catecholamine-resistant shock in ICUs. Carperitide (recombinant ANP) is approved in Japan but not the United States.

Everything else in this guide — RGDS, endothelin-1, angiotensin-(1-7), and native unmodified angiotensin-II peptide outside the Giapreza context — is research-grade material. These peptides are used in in-vitro receptor studies, in-vivo animal models, and occasionally in small mechanistic human studies under institutional protocols. They are not available as prescription medications. Commercial vendors supplying these peptides as "research chemicals" operate in the same regulatory gray zone as other research peptides.

For clinicians, the practical takeaway is that the peptide toolkit in cardiovascular medicine is narrow but pharmacokinetically valuable. For researchers, the opportunity space — antithrombotic selectivity, natriuretic-peptide-based heart-failure pharmacology, angiotensin-(1-7) analogs with improved half-life, and ET-1-pathway modulation — remains broad and active. For consumers considering research peptides, the key caveat is that none of the molecules in this guide (with the exception of the FDA-approved drugs) are appropriate for self-administration; cardiovascular peptides alter hemodynamics and coagulation in ways that demand monitored clinical settings.